Adage Capital Partners’s Acorda Therapeutics ACOR Stock Holding History

Adage Capital Partners’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,667	Closed	-$1.53M	–	770
2019 Q2	$1.53M	Buy	1,667 +1,042	+167%	+$1.28M	﹤0.01%	671
2019 Q1	$997K	Buy	+625	New	+$1.13M	﹤0.01%	660
2017 Q1	–	Sell	-6,667	Closed	-$15M	–	754
2016 Q4	$15M	Hold	6,667	–	–	0.04%	439
2016 Q3	$16.7M	Sell	6,667 -3,125	-32%	-$9.32M	0.05%	415
2016 Q2	$30M	Sell	9,792 -1,549	-14%	-$5.04M	0.08%	285
2016 Q1	$36M	Sell	11,341 -11,801	-51%	-$49M	0.1%	246
2015 Q4	$119M	Buy	23,142 +8,142	+54%	+$35.6M	0.31%	96
2015 Q3	$47.7M	Buy	15,000 +6,667	+80%	+$25.9M	0.13%	207
2015 Q2	$33.3M	Hold	8,333	–	–	0.08%	301
2015 Q1	$33.3M	Sell	8,333 -1,667	-17%	-$7.63M	0.08%	308
2014 Q4	$49M	Buy	10,000 +1,667	+20%	+$7.15M	0.12%	235
2014 Q3	$33.9M	Buy	+8,333	New	+$31.3M	0.08%	285

Other funds holding ACOR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners's ACOR Position: Q3 2019 in Review

Adage Capital Partners sold out of Acorda Therapeutics (ACOR) in Q3 2019, closing a stake of 1,667 shares — an estimated $1.53M sold.

Adage Capital Partners first reported a position in ACOR in Q3 2014 and held it in 12 quarters. The position peaked at $119M in Q4 2015. 151 funds tracked by Wall St. Rank hold ACOR as of Q3 2019.

Adage Capital Partners reported no remaining Acorda Therapeutics position as of Q3 2019 after selling out during the quarter.
Adage Capital Partners sold 1,667 Acorda Therapeutics shares in Q3 2019, an estimated $1.53M.
Adage Capital Partners first reported a position in Acorda Therapeutics in Q3 2014 and held it in 12 quarters.
Adage Capital Partners's Acorda Therapeutics position peaked at $119M in Q4 2015.
151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2019.

Based on Adage Capital Partners's 13F filing for Q3 2019, filed 14 Nov 2019.